drugset / Trial / NCT05121870
Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis
Phase 2
Unknown
240 enrolled
Beijing 302 Hospital
Chinese PLA General Hospital · collabLanZhou University · collabRenmin Hospital of Wuhan University · collabShanghai Changzheng Hospital · collabVcanbio Cell and Gene Engineering Corp., Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Decompensated cirrhosis has a high overall mortality rate. There is a large unmet need for safe and alternative therapeutic potions. This clinical trial is to inspect the efficiency and safety of mesenchymal stem cells (MSCs) therapy for decompensated cirrhosis.
Timeline
- Start
- 2021-09-01
- Primary completion
- 2023-06-30
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mesenchymal stem cells | Cell therapy | 6e+07 cells | Intravenous |